GLENMARK — Glenmark Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Annual income statement for Glenmark Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	R2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	123,049	115,832	118,131	133,217	169,825
Cost of Revenue
Gross Profit	73,261	68,849	68,101	84,330	117,345
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	107,258	112,833	121,006	118,292	152,454
Operating Profit	15,791	3,000	-2,875	14,926	17,371
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	14,412	2,398	365	13,992	19,847
Provision for Income Taxes
Net Income After Taxes	9,936	-896	-18,309	10,471	13,620
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	9,417	2,972	-15,017	10,471	13,619
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,417	2,972	-15,017	10,471	13,619
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	39.9	11.5	-46.6	47	103
Dividends per Share